These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 33647726)

  • 1. Intranasal esketamine: From origins to future implications in treatment-resistant depression.
    Sanders B; Brula AQ
    J Psychiatr Res; 2021 May; 137():29-35. PubMed ID: 33647726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.
    Kryst J; Kawalec P; Pilc A
    Expert Opin Pharmacother; 2020 Jan; 21(1):9-20. PubMed ID: 31663783
    [No Abstract]   [Full Text] [Related]  

  • 3. Esketamine: A Novel Option for Treatment-Resistant Depression.
    Bozymski KM; Crouse EL; Titus-Lay EN; Ott CA; Nofziger JL; Kirkwood CK
    Ann Pharmacother; 2020 Jun; 54(6):567-576. PubMed ID: 31795735
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compounded intranasal racemic ketamine for major depressive disorder: A case report.
    Ziegler L; Peters E; Wanson A; Halpape K
    Exp Clin Psychopharmacol; 2021 Dec; 29(6):750-754. PubMed ID: 33661659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal esketamine: A novel drug for treatment-resistant depression.
    Khorassani F; Talreja O
    Am J Health Syst Pharm; 2020 Aug; 77(17):1382-1388. PubMed ID: 32729898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: A systematic review and meta-analysis.
    Seshadri A; Prokop LJ; Singh B
    J Affect Disord; 2024 Jul; 356():379-384. PubMed ID: 38537759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression.
    Gutierrez G; Swainson J; Ravindran N; Lam RW; Giacobbe P; Karthikeyan G; Kowara A; Do A; Baskaran A; Nestor SM; Kang MJY; Biorac A; Vazquez G
    Psychiatry Res; 2024 Oct; 340():116125. PubMed ID: 39128167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis.
    Papakostas GI; Salloum NC; Hock RS; Jha MK; Murrough JW; Mathew SJ; Iosifescu DV; Fava M
    J Clin Psychiatry; 2020 May; 81(4):. PubMed ID: 32459407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial.
    Smith-Apeldoorn SY; Veraart JKE; Kamphuis J; van Asselt ADI; Touw DJ; Aan Het Rot M; Schoevers RA
    BMC Psychiatry; 2019 Nov; 19(1):375. PubMed ID: 31783823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study.
    Singh B; Kung S; Pazdernik V; Schak KM; Geske J; Schulte PJ; Frye MA; Vande Voort JL
    J Clin Psychiatry; 2023 Feb; 84(2):. PubMed ID: 36724113
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
    Jesus-Nunes AP; Leal GC; Correia-Melo FS; Vieira F; Mello RP; Caliman-Fontes AT; Echegaray MVF; Marback RF; Guerreiro-Costa LNF; Souza-Marques B; Santos-Lima C; Souza LS; Bandeira ID; Kapczinski F; Lacerda ALT; Quarantini LC
    Hum Psychopharmacol; 2022 Jul; 37(4):e2836. PubMed ID: 35179810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
    JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacology of ketamine and esketamine as rapid-acting antidepressants].
    Pavlidi P; Megalokonomou A; Sofron A; Kokras N; Dalla C
    Psychiatriki; 2021 Dec; 32(Supplement I):55-63. PubMed ID: 34990380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients.
    Banov MD; Landrum RE; Moore MB; Szabo ST
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):594-599. PubMed ID: 34411009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy: Ketamine and Esketamine.
    Feeney A; Papakostas GI
    Psychiatr Clin North Am; 2023 Jun; 46(2):277-290. PubMed ID: 37149345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine.
    De Berardis D; Tomasetti C; Pompili M; Serafini G; Vellante F; Fornaro M; Valchera A; Perna G; Volpe U; Martinotti G; Fraticelli S; Di Giannantonio M; Kim YK; Orsolini L
    Curr Top Med Chem; 2020; 20(7):554-584. PubMed ID: 32003691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
    Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Esketamine for treatment resistant depression.
    Swainson J; Thomas RK; Archer S; Chrenek C; MacKay MA; Baker G; Dursun S; Klassen LJ; Chokka P; Demas ML
    Expert Rev Neurother; 2019 Oct; 19(10):899-911. PubMed ID: 31282772
    [No Abstract]   [Full Text] [Related]  

  • 20. The antidepressant effect and safety of non-intranasal esketamine: A systematic review.
    Smith-Apeldoorn SY; Vischjager M; Veraart JK; Kamphuis J; Aan Het Rot M; Schoevers RA
    J Psychopharmacol; 2022 May; 36(5):531-544. PubMed ID: 35546042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.